Abstract:Nanomedicines have achieved several successful clinical applications for cancer therapy over the past decades. To date, numerous nanomedicine formats and design rationales have been proposed to improve pharmaceutical delivery and treatment efficacy. Despite these advances, the achievement of high drug loading and loading efficiencies of drug payloads in nanocarriers remains a technical challenge. In addition, study of the correlation between therapeutic potential and drug loading has been ignored. Here, using a self-assembling dimeric cabazitaxel prodrug, we show that the prodrug can be quantitatively entrapped within clinically approved polymer matrices for intravenous injection and that the drug loading in the nanoparticles (NPs) is tunable. The engineered NPs (NPs1-4) with different drug loading values exhibit dissimilar morphologies, release kinetics, in vitro cytotoxic activity, pharmacokinetic properties, tissue distribution, and in vivo anticancer efficacy and safety profiles. Furthermore, the effect of drug loading on the treatment outcomes was explored through detailed in vitro and in vivo studies. Intriguingly, among the constructed NPs, those comprising poly(ethylene glycol)-block-poly(D,L-lactic acid) (PEG-PLA) copolymers showed substantially prolonged pharmacokinetic properties in the blood circulation, which further promoted their intratumoral delivery and accumulation. Furthermore, the PEG-PLA-composed NPs with high drug loading (~50%) demonstrated favorable efficacy and safety profile in animal models. These data provide convincing evidence that the in vivo performance of a given self-assembling drug is not compromised by high drug loading in nanoplatforms, which may potentially reduce concerns over excipient-associated side effects and immunotoxicities. Overall, our study provides new insight into the rationale for designing more effective and less toxic delivery systems.

Self-assembled lipid− polymer hybrid nanoparticles: a robust drug delivery platform

Nanoparticle-Hydrogel: A Hybrid Biomaterial System for Localized Drug Delivery

Lipid–polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives

Lipid-Polymer Hybrid Nanosystems: A Rational Fusion for Advanced Therapeutic Delivery

Stable Polymer Nanoparticles with Exceptionally High Drug Loading by Sequential Nanoprecipitation

Microfluidic synthesis of multilayered lipid-polymer hybrid nanoparticles for the formulation of low solubility drugs

Ultra-small Lipid-Polymer Hybrid Nanoparticles for Tumor-Penetrating Drug Delivery.

A hyperbranched amphiphilic acetal polymer for pH-sensitive drug delivery

Nanodelivery of a Self-Assembling Prodrug with Exceptionally High Drug Loading Potentiates Chemotherapy Efficacy.

Nanoemulsion-Templated Shell-Crosslinked Nanocapsules As Drug Delivery Systems

Development of a concentration‐controlled sequential nanoprecipitation for making lipid nanoparticles with high drug loading

Micelle-like nanoassemblies based on polymer-drug conjugates as an emerging platform for drug delivery.

Lipid-Polymer Hybrid Nanoparticles Synthesized via Lipid-Based Surface Engineering for a robust drug delivery platform

Self-Assembly of Biocompatible Core-Shell Nanocapsules with Tunable Surface Functionality by Microfluidics for Enhanced Drug Delivery

One-step Preparation of Biocompatible Amphiphilic Dimer Nanoparticles with Tunable Particle Morphology and Surface Property for Interface Stabilization and Drug Delivery

Design of nanocarriers for nanoscale drug delivery to enhance cancer treatment using hybrid polymer and lipid building blocks

Polymer Vesicles and Lipid Nanoparticles

Self-assembled lipid nanostructures encapsulating nanoparticles in aqueous solution

An update on strategies for optimizing polymer-lipid hybrid nanoparticle-mediated drug delivery: exploiting transformability and bioactivity of PLN and harnessing intracellular lipid transport mechanism

Synthetically Tunable Suprahybrid Nanoparticle Platform for the Efficacious Delivery of Therapeutics

Development of Multinuclear Polymeric Nanoparticles As Robust Protein Nanocarriers.